Ipsen – Option agreement to acquire Canbex Therapeutics – Businesswire

Ipsen will complement its portfolio with the acquisition of the UK biotech, Canbex Therapeutics

MS_and_the_Brain_DamageCanbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as VSN16R (Phase I successfully completed). As stated by Marc de Garidel, Chairman and CEO of Ipsen, “it could be a valuable companion product to Dysport® in the treatment of spasticity”. Read more

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s